Reduction of cardiac and renal dysfunction by new inhibitor of DPP4 in diabetic rats

Increased mortality due to type 2 diabetes mellitus (T2DM) has been associated with renal and/or cardiovascular dysfunction. Dipeptidyl dipeptidase-4 inhibitors (iDPP-4s) may exert cardioprotective effects through their pleiotropic actions via glucagon-like peptide 1-dependent mechanisms. In this st...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacological reports 2019-11, Vol.71 (6), p.1190
Main Authors: Alves, Bryelle E O, de Alencar, Allan K N, Gamba, Luis E R, Trachez, Margarete M, da Silva, Jaqueline S, Araújo, Josenildo S C, Montagnoli, Tadeu L, Mendes, Luiza V P, Pimentel-Coelho, Pedro M, Cunha, Valéria do M N, Mendez-Otero, Rosalia, Oliveira, Gláucia M M, Lima, Lídia M, Barreiro, Eliezer J, Sudo, Roberto T, Zapata-Sudo, Gisele
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Increased mortality due to type 2 diabetes mellitus (T2DM) has been associated with renal and/or cardiovascular dysfunction. Dipeptidyl dipeptidase-4 inhibitors (iDPP-4s) may exert cardioprotective effects through their pleiotropic actions via glucagon-like peptide 1-dependent mechanisms. In this study, the pharmacological profile of a new iDPP-4 (LASSBio-2124) was investigated in rats with cardiac and renal dysfunction induced by T2DM. T2DM was induced in rats by 2 weeks of a high-fat diet followed by intravenous injection of streptozotocin. Metabolic disturbance and cardiac, vascular, and renal dysfunction were analyzed in the experimental groups. Sitagliptin and LASSBio-2124 administration after T2DM induction reduced elevated glucose levels to 319.8 ±13.2 and 279.7 ± 17.8 mg/dL, respectively (p
ISSN:1734-1140